In this regard, niclosamide, a transcriptional inhibitor of S100A4, undergoing repurposing for numerous inflammatory and fibrotic diseases [77,78,79], has shown beneficial effects in diminishing gliosis and axonal impairment in a model of ALS, and in improving peripheral neuropathy [80], representing a promising drug for treating nervous system diseases. The gene discussed is S100A4; the disease is amyotrophic lateral sclerosis.